Nusinersen

Overview

Nusinersen is an antisense oligonucleotide used in the treatment of spinal muscular atrophy (SMA) by increasing the expression of functional survival motor neuron (SMN) protein. It works by modulating splicing of the SMN2 gene.

API suppliers (1)

Suppliers of Nusinersen backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• SHANGHAI SINUOTIDES BIOPHARMACEUTICAL CO LTD2 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (3 approved US products), the latest listed US patent on Nusinersen expires 4 Mar 2036. Generic API sourcing typically opens up once these lapse.

Therapeutic areas